Semaglutide Treatment Boosts Employment and Working Hours in Denmark
Diabetes and weight-loss medications like semaglutide generate economic effects that extend past healthcare spending, according to a study published as a discussion paper by the Centre for Economic Policy Research (CEPR) and reported by Mirage News. Using population-wide Danish records from 2018 to 2024, researchers at NYU Abu Dhabi tracked employment rates, working hours, and earnings around the time individuals initiated treatment with medications such as Ozempic and Wegovy.
Both drugs belong to a class of medications called GLP-1 receptor agonists, which mimic a natural hormone that regulates blood sugar and appetite. The study distinguishes between patients receiving subsidized Ozempic for Type 2 diabetes and those paying out of pocket for Wegovy for weight management, uncovering distinct labor market outcomes for each group.
Labor Market Impacts of Ozempic and Wegovy
For individuals receiving subsidized Ozempic treatment for diabetes, the therapy generated a 4.1 percentage-point increase in the probability of employment. It also produced an increase of 19.5 hours in total working hours per quarter.
Among patients paying out of pocket for Wegovy for weight management, treatment showed no statistically significant change in the likelihood of entering employment. However, individuals in this group who were already employed worked an additional 29.7 hours per quarter.
These findings highlight the importance of looking beyond the direct costs of medication when examining its wider economic effects,
said Assistant Professor of Economics Veda Narasimhan at NYU Abu Dhabi, as reported by Mirage News. By examining employment and working hours separately, we can better understand how outcomes differ between treatment groups and the potential implications for individuals and public finances.
Taking Wegovy, Ozempic? Abu Dhabi study reveals economic benefits of weight-loss drugshttps://t.co/KoJtL03Hh4
Fiscal Effects on Public Finances and Tax Revenue
The NYU Abu Dhabi research team evaluated how shifts in employment and working hours translate to public finances under Denmark’s specific healthcare and tax arrangements. Because diabetes treatment is subsidized while Wegovy users pay out of pocket, the fiscal dynamics vary by condition.
The study’s fiscal analysis estimates that additional income tax revenue generated by increased labor income among Ozempic and Wegovy users could help offset public spending on subsidized diabetes treatment. Researchers argue that evaluating therapies solely through clinical metrics overlooks broader economic returns.
Evaluating healthcare treatments purely through clinical metrics like weight loss or blood sugar levels misses the bigger picture. We need to look beyond direct medical costs,
said Raül Santaeulàlia-Llopis, Associate Professor of Economics at NYU Abu Dhabi, according to Mirage News. Our research shows that when you account for changes in employment, working hours, and the resulting tax revenues, the fiscal calculus changes entirely.
Future Research on Lifestyle and Pharmaceutical Dependency
The CEPR discussion paper establishes a link between semaglutide treatment and labor market metrics, but researchers emphasize that broader questions remain regarding long-term patient outcomes and lifestyle factors.
Santaeulàlia-Llopis noted that a complete analysis must examine how these medications influence lifestyle choices such as diet and exercise. The NYU Abu Dhabi team is currently investigating these dynamics through ongoing work with the Abu Dhabi Department of Health on the Thiqa obesity program, aiming to determine whether GLP-1 treatments act as catalysts for sustainable healthy habits or establish new forms of pharmaceutical dependency.
Medications Studied in Research
What specific medications did the NYU Abu Dhabi researchers study?
The study examined semaglutide, which is sold under the brand name Ozempic for Type 2 diabetes and Wegovy for weight management.
How were the data collected for this labor market study?
Researchers analyzed population-wide Danish records from 2018 to 2024, tracking employment, working hours, and earnings around the time participants began their treatments.
What is the difference in payment structures for these drugs in Denmark?
In Denmark, diabetes treatment utilizing Ozempic is subsidized by the public healthcare system, whereas patients utilizing Wegovy for weight management pay the full cost out of pocket.
Worth a look